🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Betta Pharmaceuticals clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Betta Pharmaceuticals as lead sponsor. Synced 26 Sep 2026
15Current trials
12Recruiting now
7Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Betta Pharmaceuticals is the lead sponsor of 15 current clinical trials in our China register. 12 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are MCLA-129, Befotertinib and Carboplatin. The most-studied condition is Non-Small Cell Lung Cancer.

ClinicalTrials.gov trials by status

  • Recruiting1280%
  • Not yet open213%
  • Active, closed17%

Trials by phase

  • Phase 1853%
  • Phase 1/2320%
  • Phase 2213%
  • Observational17%
  • Phase 317%
01

Clinical trials sponsored by Betta Pharmaceuticals

15 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Drug-Drug Interaction Study of Vorolanib Tablets in Healthy Participants
NCT07809789 · ClinicalTrials.gov ↗ · DDI (Drug-Drug Interaction)
Phase 1 Recruiting 2026-09 China
Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer
NCT07806604 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer)
Drug: Icotinib
Observational Recruiting 2026-09 China
Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.
NCT07448116 · ClinicalTrials.gov ↗ · Solid Advanced Tumor
Phase 1/2 Recruiting 2026-01 China
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
NCT06041776 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
Phase 3 Recruiting 2023-03 China
A Phase I Study of CFT8919 in Patients With Advanced NSCLC
NCT06641609 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer With EGFR Mutation
Phase 1 Recruiting 2024-11 China
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT07435038 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1/2 Recruiting 2026-01 China
A Study of BPI-460372 in Advanced Solid Tumor Patients
NCT05789602 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1 Recruiting 2023-04 China
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
NCT05341557 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Lymphoma, NSCLC
Phase 1 Recruiting 2022-08 China
Drug-Drug Interaction Study of Befotertinib Capsules in Healthy Participants.
NCT07809815 · ClinicalTrials.gov ↗ · DDI (Drug-Drug Interaction)
Phase 1 Recruiting 2026-09 China
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
NCT04930432 · ClinicalTrials.gov ↗ · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer
Drug: MCLA-129
Phase 1/2 Recruiting 2021-09 China
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
NCT07181499 · ClinicalTrials.gov ↗ · NSCLC, Adjuvant Drug Therapy, EGFR
Phase 2 Recruiting 2025-09 China
Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic Impairment
NCT07809802 · ClinicalTrials.gov ↗ · Hepatic Impairment (HI)
Drug: Vorolanib
Phase 1 Recruiting 2026-09 China
Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
NCT06015568 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
Phase 1 Not yet open 2023-09 China
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
NCT06885840 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Drug: MCLA-129
Phase 2 Not yet open 2025-03 China
A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor
NCT03791112 · ClinicalTrials.gov ↗ · Advanced Solid Cancer
Phase 1 Active, closed 2019-07 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Betta Pharmaceuticals trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Betta Pharmaceuticals trials

23 conditions
Non-Small Cell Lung Cancer3DDI (Drug-Drug Interaction)2Advanced Solid Tumor2NSCLC2Non-Small Cell Lung Cancer、EGFR Sensitive Mutation1NSCLC (Non-small Cell Lung Cancer)1Solid Advanced Tumor1EGFR Sensitive Mutation1Adjuvant Therapy1Non-Small Cell Lung Cancer With EGFR Mutation1Advanced Solid Cancer1Non-small Cell Lung Cancer (NSCLC)1Colorectal Cancer (CRC)1Pancreatic Ductal Adenocarcinoma (PDAC)1Advanced Solid Tumors1Lymphoma1HCC1Solid Tumor1Head and Neck Cancer1Colorectal Cancer1Adjuvant Drug Therapy1EGFR1Hepatic Impairment (HI)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China1512

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Non-Small Cell Lung Cancer

SponsorTrials
Sichuan Baili Pharmaceutical15
AstraZeneca13
Merck Sharp & Dohme9
Hoffmann-La Roche7
Daiichi Sankyo5
Hunan Province Tumor Hospital5
Shanghai Pulmonary Hospital, Shanghai, China4
Shanghai Chest Hospital4
BioNTech3
Dizal Pharmaceuticals3

Sponsors with the most current trials registered for this condition.

06

Questions about Betta Pharmaceuticals trials

How many clinical trials does Betta Pharmaceuticals sponsor?

Betta Pharmaceuticals is the lead sponsor of 15 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Betta Pharmaceuticals trials recruiting?

Yes. 12 of its 15 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Betta Pharmaceuticals testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are MCLA-129 (4), Befotertinib (2), Carboplatin (1), Ensartinib (1) and Icotinib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.